SLS Stock Extends Rally Overnight: CEO Says ‘Bullish’ Leukemia Data Could Drive NCCN Recognition For GPS
Sellas Life Sciences Group (SLS) shares rose about 2% overnight after CEO Angelos Stergiou said he is “very bullish” on Phase 3 Regal trial data for galinpepimut-S (GPS) in AML. The trial has reached 78 of 80 events, with final analysis after the 80th. Stergiou said positive results could support NCCN recognition and cited prior survival projections.
How this was made
The 30-second read
Why it matters
CEO commentary at TD Cowen’s oncology summit emphasizes bullish expectations for Regal data and potential NCCN guideline expansion, while the trial has reached 78 of 80 events.
Market read
Traders are likely to treat this as a momentum catalyst for SLS into the next Regal milestone, but the real decision point remains topline data after the 80th event.
What to watch
The article does not provide a new survival estimate or updated event-based hazard; traders may be over-weighting CEO interpretation versus the actual final-analysis data at the 80th event.
Background
Sellas’ flagship AML immunotherapy GPS is in a Phase 3 Regal trial, with final analysis triggered by the 80th required event.
Ticker impact
Sellas CEO said he is “very bullish” on Regal Phase 3 GPS data that could support NCCN recognition, with 78/80 events reached and 80th event as final-analysis trigger.
Bias toward continued momentum/optionality into the next Regal milestone, with downside risk if event timing or survival benefit disappoints at topline.
The article adds a fresh CEO quote and specific trial status (78 of 80 events, 80th triggers analysis) plus NCCN guideline speculation, but it does not disclose new survival results or a scheduled readout date.
Market effects
Reinforces risk-on sentiment for AML immunotherapy developers ahead of Phase 3 readouts, though impact is company-specific.
No clear regional spillover beyond US biotech sentiment.
Limited global relevance; story is centered on a single US-listed biotech’s trial milestone and potential guideline positioning.
Counterpoint
NCCN recognition is conditional and speculative; longer-than-projected event timing can also reflect operational delays rather than superior outcomes.
Key entities
- companySellas Life Sciences Group
Subject of the article; CEO comments link Regal trial progress to potential NCCN recognition for GPS in AML.
- clinical_trialRegal trial (Phase 3)
Phase 3 study of galinpepimut-S (GPS) in AML CR2 patients not eligible for stem cell transplant; 78/80 events reached.
- drugGPS (galinpepimut-S)
Sellas’ WT1-targeted immunotherapy; CEO suggests potential NCCN guideline support and possible maintenance role.
- drugSLS009
Sellas’ CDK9 inhibitor in Phase 2; topline data expected later this year and potential accelerated approval depending on results.
